Insider buying last 90 days
No open-market insider purchases were filed for BCPC in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every BCPC insider filing, plotted on the chart in Gekko.Open BCPC in Gekko
NASDAQ: BCPC
Balchem (BCPC) Stock Analysis & Forecast
Sep 28 close
$168.68+0.79 (+0.5%)
Gekko Brief
AI summaryBalchem draws attention this week mainly from analyst commentary rather than company news. Argus raised its target price for BCPC to $185.00, up from its prior price reference of $167.84, while a separate cash-flow-based analysis points to the stock trading below its calculated intrinsic value, citing last-twelve-month free cash flow of $177.6 million. A filing also disclosed the R&D chief's holdings, including restricted shares that vest over one to three years.
Shares closed at $168.68, up 0.5%, sitting between the 50-day average of $171.63 and the 200-day average of $168.30, reflecting a mixed trend picture. The stock has returned -5.2% over one month but is roughly flat over three months and up 3.3% over the past year. The GekkoIndex reads 58.4, placing BCPC in the Neutral zone, and the price sits 4% below Gekko Fair Value of $175.69.
Balchem reports earnings on 20 October 2026, 21 days away, which falls inside a typical 20-trading-day holding window; the prior quarter beat estimates with EPS of $1.33 versus $1.24 expected, though the stock reacted -0.8%. Over the last 90 days, Congress recorded 2 buys and 0 sales. Seasonally, the next 20 trading days have averaged a 1.6% gain over 4 years, rising in 2 of them, a mixed historical pattern worth noting.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Balchem price vs fair value
Close $168.68200-day averageGekko Fair Value $175.69
Balchem quick facts
- Market cap
- $5.42B
- P/E ratio
- 33
- Forward P/E
- 29.3
- EPS, TTM
- $5.08
- Revenue, TTM
- $1.09B
- Profit margin
- 15.1%
- Dividend yield
- 0.57%
- Beta
- 0.81
- Volume
- 134,616 avg 188,790
- 1-year return
- +3.3%
- Typical daily move
- ±1.9%
- Typical 20-day move
- ±4.9%
- 50-day average
- $171.63
- 200-day average
- $168.30
- Next earnings
- Oct 20
- Shares outstanding
- 31.88M
Balchem swing-trade checklist
Balchem scores 1 supportive, 4 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
1 supportive4 mixed1 headwind
- Trendmixed
Averages disagree
Close $168.68 sits between the 50-day ($171.63) and 200-day ($168.30) averages, or the averages disagree.
See the chart - GekkoIndexmixed
58.4, Neutral
Reading 58.4 is in the Neutral zone.
See the GekkoIndex - Fair valuemixed
4.0% below
Price is within 5% of Gekko Fair Value (4% below).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: Congress 2 buys / 0 sales.
See smart money - Earnings riskheadwind
Reports in 21 days
Reports on Oct 20, 2026, 21 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+1.6% on average
From this point in the calendar, the next 20 trading days averaged +1.6% over 4 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Balchem stock chart and price history
Balchem closed at $168.68 on Sep 28, 2026, +3.3% over the past year, inside a 52-week range of $145.70 to $183.90.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −5.2%
- 3 months
- −0.3%
- 6 months
- +1.0%
- 1 year
- +3.3%
The full BCPC chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BCPC in Gekko
Follow Balchem through every session
Put BCPC on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track BCPC in GekkoFree for 7 days. No credit card required.
About Balchem
Balchem produces specialty ingredients that reach into food, pharmaceutical, animal care, medical sterilization, plant nutrition, and industrial uses around the world. Among its offerings are encapsulated nutrients, vitamin K2, choline-derived compounds, mineral chelates, and gases applied in sterilizing medical equipment, which together give the company recognition across several markets.
Its operations fall into three areas. One focuses on ingredients for food and drink makers, supplying items such as dried powders, lipid blends, flavor systems, and bases used in dairy, juice, chocolate, cereal, and ice cream production. Another serves animal health, offering nutrient delivery methods and absorption-enhancing chelation technology for livestock and pets alike. A third handles specialty distribution, moving ethylene oxide and ammonia for hospital sterilization work, fumigants that guard nuts, spices, cacao, and dried fruit from pests and spoilage, and mineral chelates for agricultural crops. Balchem reaches its customers directly and also relies on outside distributors and agents to move its goods to market.
Founded in 1967, the company keeps its headquarters in Montvale, New Jersey, and its stock is listed on the NASDAQ under the ticker BCPC.
- Listed
- NASDAQ
- Sector
- Consumer non-durables
- Industry
- Food: specialty/candy
- Website
- balchem.com
Balchem GekkoIndex: the smart money zone
Balchem’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 58.4, in the Neutral zone, down 6 points over five sessions.
58.4Neutral
Down 6 points over five sessions, from the Accumulation zone.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 29 | +1.0% | +3.8% | ||
| Accumulation | 146 | +0.7% | +4.1% | ||
| Neutral (current zone) | 343 | −0.1% | −0.6% | ||
| Distribution | 23 | +1.1% | −0.6% | ||
| Selling | 4 | Too few readings yet | |||
Average BCPC share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the BCPC price, zone by zone.Track BCPC in Gekko
Is Balchem stock overvalued? Gekko Fair Value
Balchem trades 4.0% below Gekko Fair Value of $175.69, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Balchem shares are worth, recalculated every trading day.
$175.69
Gekko Fair Value, Sep 26, 2026
4.0% below fair value · About fair value
Gekko Fair Value on every chart, with the gap to price updating daily.Open BCPC in Gekko
Balchem insider and Congress trading
No open-market insider purchases were filed for Balchem, and members of Congress disclosed 2 purchases and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
2trades disclosed: 2 purchases and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Gilbert Ray Cisneros House, CA, purchase | $1,001 - $15,000 | Sep 7 traded Jul 10 |
| Gilbert Ray Cisneros House, CA, purchase | $1,001 - $15,000 | Sep 7 traded Jul 9 |
From congressional disclosures, which report amounts as ranges.
Buybacks
Balchem has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $28.79M
- As a share of market cap
- 0.53%
- Trailing four quarters
- $113.5M
From company filings.
Balchem earnings: next date and track record
Balchem reports on Oct 20, 2026 (21 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Oct 20, 2026
21 days away
- EPS estimate
- $1.43
- Revenue estimate
- $289.2M
7 of 8reports beat the EPS estimate
±1.8%average move across the report
7 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Apr 24, 2026 | $1.33 est $1.24 | — | −0.8% |
| Feb 13, 2026 | $1.31 est $1.18 | $263.6M est $259.6M | +1.1% |
| Oct 21, 2025 | $1.35 est $1.36 | $267.6M est $259.6M | +0.4% |
| Jul 24, 2025 | $1.27 est $1.11 | $255.5M est $257.6M | +0.4% |
| May 1, 2025 | $1.22 est $1.22 | $250.5M est $245.7M | +3.4% |
| Feb 14, 2025 | $1.13 est $1.11 | — | +1.8% |
| Oct 25, 2024 | $1.13 est $1.11 | $239.9M est $235.1M | +2.8% |
| Jul 26, 2024 | $1.09 est $1.03 | $234.1M est $239.7M | +3.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Balchem stock forecast and analyst price targets
Analysts’ average 12-month price target for Balchem is $209.25, +24.1% from the last close, from 1 firm rating the stock in the last 90 days.
$209.25consensus 12-month target, +24.1% from the last close
Each firm’s latest rating in the last 90 days: 1 firm.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Aug 3 | H.C. Wainwright | $215 | +27.5% |
−0.6%average 20-day move after past Neutral readings
+1.6%average move over the next 20 trading days in the last 4 years
±1.9%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Balchem seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Balchem averaged +1.6% across the last 4 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.3% | 3 of 4 |
| Next 10 trading days | +1.4% | 3 of 4 |
| Next 15 trading days | +1.5% | 2 of 4 |
| Next 20 trading days | +1.6% | 2 of 4 |
| Next 30 trading days | +6.4% | 3 of 4 |
For scale, BCPC’s typical 20-trading-day move in either direction is about 4.9%.
Balchem market cap and key statistics
Balchem’s market cap is $5.42B, with a P/E ratio of 33 and revenue of $1.09B over the last twelve months.
Valuation
- Market cap
- $5.42B
- P/E ratio
- 33
- Forward P/E
- 29.3
- EPS, TTM
- $5.08
- Gekko Fair Value
- $175.69
Trading
- Volume
- 134,616
- Avg volume, 20 days
- 188,790
- 52-week high
- $183.90
- 52-week low
- $145.70
- Shares outstanding
- 31.88M
Financials
- Revenue, TTM
- $1.09B
- Profit margin
- 15.1%
- Return on equity
- 12.8%
- Quarterly earnings growth, YoY
- +18.8%
Risk and income
- Beta
- 0.81
- Typical daily move
- ±1.9%
- Typical 20-day move
- ±4.9%
- Dividend yield
- 0.57%
Balchem stock news this week
Coverage of Balchem this week reads positive: 2 positive, 1 neutral and 0 negative headlines.
- Most of the shares held directly by Balchem's (BCPC) R&D chief are restricted and vest over time.Stock Titan, Sep 24
- Balchem Corporation (BCPC) Stock forecastsYahoo Finance Singapore, Sep 24
- Balchem (BCPC) Stock Could Be 25% Undervalued On Cash FlowSimply Wall Street, Sep 24
Balchem peers
Balchem’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| PEPPepsiCo | Buying | 17.5% below |
| MDLZMondelez International | Accumulation | 19.9% below |
| HSYHershey | Buying | 30.4% below |
| IFFInternational Flavors & Fragrances | Neutral | 2.9% below |
| MKCMcCormick | Accumulation | 15.4% below |
| SJMJ.M. Smucker | Accumulation | 7.5% above |
A peer links to its own page where one exists.
Balchem stock FAQ
What is Balchem’s market cap?
Balchem’s market cap is $5.42B at the Sep 28, 2026 close of $168.68, with 31.88M shares outstanding. The shares trade on a P/E ratio of 33.
What is the Balchem stock forecast?
The consensus analyst 12-month price target for Balchem is $209.25, +24.1% from the last close. Of the 1 firm that rated the stock in the last 90 days, 1 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Balchem stock overvalued or undervalued?
On Gekko’s estimate Balchem is about fair value: the Sep 28, 2026 close of $168.68 is 4.0% below Gekko Fair Value of $175.69. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Balchem report earnings next?
Balchem is expected to report on Oct 20, 2026 (21 days away). Analysts expect earnings of $1.43 per share on revenue of $289.2M. Balchem beat the earnings estimate in 7 of its last 8 reports, moving 1.8% on average across the report.
What is Balchem’s 52-week high and low?
Balchem’s 52-week high is $183.90 and its 52-week low is $145.70; it closed at $168.68 on Sep 28, 2026, +3.3% over the past year. Over the last five years the shares peaked at $186.03 on Jul 29, 2024.
Is Balchem stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 1 of the 6 items with data read as supportive (smart money), 4 as mixed (trend, gekkoindex, fair value and seasonality) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Balchem the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.